# Burning Rock Biotech

Source: https://onco.cc/companies/burning-rock/  
OnCo record `burning-rock` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese cancer genomics company in Guangzhou that makes tumour sequencing tests and the OverC blood test for several cancers.

## Summary

Burning Rock Biotech, whose principal office is on Guangzhou's International Bio Island, files annual reports with the US SEC. Its 2025 annual report says it commercially launched its first cancer therapy selection test in 2014 and describes OverC, its multi-cancer detection blood test, as holding Breakthrough Device designations from the FDA (January 2023) and NMPA (October 2023) and being commercialised with a small number of pilot hospitals in China, with a second-generation test for up to 22 cancer types at an early stage.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Guangzhou
- Type: diagnostics
- Website: https://www.brbiotech.com/

## Sources

- 2025 annual report (SEC 20-F): https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/d31568d20f.htm
- Official website: https://www.brbiotech.com/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [OverC Multi-Cancer Detection Blood Test](https://onco.cc/drugs/overc-mcdbt/)
- key papers: [Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study](https://onco.cc/key-papers/paper-promise-innovation-2026/), [Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies](https://onco.cc/key-papers/paper-gao-thunder-ann-oncol-2023/)
- trials: [PERCEIVE-I (multi-omic blood test for gynaecological cancers)](https://onco.cc/trials/perceive-1/), [PERCEIVE-II (extended validation for gynaecological cancers)](https://onco.cc/trials/perceive-2/), [PREDICT (Burning Rock pan-cancer early detection project)](https://onco.cc/trials/predict-overc/), [PRESCIENT (pan-cancer early-stage detection, Chinese Academy of Medical Sciences)](https://onco.cc/trials/prescient-cams/), [PREVENT (OverC in people without symptoms)](https://onco.cc/trials/prevent-overc/), [PROMISE (pan-cancer liquid biopsy proof of concept, Chinese Academy of Medical Sciences)](https://onco.cc/trials/promise-cams/), [THUNDER (blinded validation of Burning Rock's methylation test)](https://onco.cc/trials/thunder-overc/)

---
JSON: https://onco.cc/api/v1/entities/burning-rock.json